Janux Therapeutics, Inc.
JANX
$14.05
$0.171.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.95M | -24.31M | -33.86M | -23.51M | -20.22M |
| Total Depreciation and Amortization | 468.00K | 501.00K | 541.00K | 519.00K | 512.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.99M | 4.42M | 5.75M | 6.48M | 3.32M |
| Change in Net Operating Assets | -3.06M | 6.54M | 3.75M | -516.00K | -345.00K |
| Cash from Operations | -28.54M | -12.86M | -23.81M | -17.02M | -16.73M |
| Capital Expenditure | -106.00K | -93.00K | -473.00K | -371.00K | -42.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.65M | 8.40M | 2.04M | -340.02M | 33.97M |
| Cash from Investing | 29.54M | 8.31M | 1.56M | -340.39M | 33.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.94M | 493.00K | 954.00K | 901.00K | 386.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -347.00K | -- |
| Cash from Financing | 2.94M | 493.00K | 954.00K | 554.00K | 386.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.95M | -4.06M | -21.30M | -356.86M | 403.85M |